XCDS
2.12.2020 10:36:10 CET | Business Wire | Press release
Shaping the future of teamwork is a difficult challenge and Collabio® Spaces by XCDS is ready to take it head on. After several years of stealth mode development, the team which includes former QuickOffice™ engineers released their alternative view on collaboration around documents and co-authoring. Their software works with the majority of popular office document formats and enables real time collaboration even without Internet connection and clouds. Collabio Spaces allows you to share access to your documents whilst keeping them exceptionally and solely on your private mobile or desktop device.
The next step in the app's evolution is taking part in Web Summit — the "best technology conference on the planet ", according to Forbes. Collabio Spaces team will join 100.000+ attendees, 800+ speakers and 2500+ startups on December 2-4, 2020.
The team will speak about technologies behind cloudless collaboration and real time co-authoring, present our product and meet with partners.
"We'll join Web Summit to share our ideas and get feedback from the most innovative community in our world. This is the place where the future is shaped and we'd like to place our stake in this process, " said Andy Webb, CEO.
At Web Summit, the Collabio Spaces team will hold two roundtables :
-
"Co-authoring documents. What’s good and what’s still missing"
—15:00 - 15:45 (UK Time) on Wednesday, December 2, 2020.
You'll learn how to improve your teamwork on documents and why you should pay attention to that, we will speak of which document co-editing issues are left to be resolved and how they may be fixed. Also, you'll get a bunch of useful tips for effective co-authoring, which will boost your team's productivity!
If you write or review documents, lead teams of authors and aim to achieve results at tough deadlines or want to raise the quality of final documents, we expect this roundtable will be valuable for you!
-
"Under the hood of cloudless collaboration"
— 14:00 - 15:45 (UK Time) on Thursday, December 3, 2020.
Collabio Spaces' tech team will share their hands-on experience on enabling team collaboration in a simple WiFi network. You will find out how to make an iPhone the nexus point of documents co-editing without involving any external servers. We'll discuss the magic behind this cloudless technology and the model that we fitted into the tough requirements of mobile device computing power!
Are you a tech geek or just take interest in peer-to-peer technologies and mobile applications? We're waiting for you at this roundtable!
To learn more about the App and our plans for Web Summit 2020, visit the official website and feel free to ask us any questions on socials or via email.
XCDS is a software development company that creates user-friendly and efficient office software for iOS, macOS, Windows and Linux devices, and now — our new innovative and convenient iOS app.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005090/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom